$7.71+0.08 (+1.05%)
News25/Ratings12
Price$7.71+1.67 (+27.75%)
2026-01-212026-04-24
News · 26 weeks42+400%
2025-11-022026-04-26
Mix2290d
- Insider10(45%)
- SEC Filings7(32%)
- Earnings2(9%)
- Other2(9%)
- Leadership1(5%)
Latest news
25 items- PRCVRx Announces Nomination of Michael Dale for Election to the Board of DirectorsMINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026. "Michael has achieved an outstanding record of commercial success in the medical device industry, and I'm excited for him to join our Board of Directors," said Kevin Hykes, President and CEO of CVRx. "His extensive experience leading high growth organizations, both as an executi
- SECSEC Form DEFA14A filed by CVRx Inc.DEFA14A - CVRx, Inc. (0001235912) (Filer)
- SECSEC Form DEF 14A filed by CVRx Inc.DEF 14A - CVRx, Inc. (0001235912) (Filer)
- SECCVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
- PRCVRx Reports Preliminary First Quarter 2026 Financial ResultsDelivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior authorizations managed by our market access teamFirst site activated in BENEFIT-HF clinical trial MINNEAPOLIS, April 13, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited first quarter 2026 financial
- INSIDERChief Medical Officer Adamson Philip B. was granted 41,000 shares and sold $9,973 worth of shares (1,262 units at $7.90), increasing direct ownership by 182% to 61,578 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERCHIEF HUMAN RESOURCES OFFICER Morrison Gregory was granted 34,000 shares (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERSEC Form 3 filed by new insider Morrison Gregory3 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERPRES & CEO Hykes Kevin sold $61,349 worth of shares (7,763 units at $7.90) and was granted 159,000 shares, increasing direct ownership by 114% to 284,237 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERCHIEF MKTG & STRAT OFFICER Verrastro Paul was granted 45,000 shares and sold $10,146 worth of shares (1,284 units at $7.90), increasing direct ownership by 260% to 60,551 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Oasheim Jared was granted 61,000 shares and sold $13,781 worth of shares (1,744 units at $7.90), increasing direct ownership by 158% to 96,703 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERChief Revenue Officer John Robert Allen was granted 35,000 shares and sold $31,326 worth of shares (3,964 units at $7.90), increasing direct ownership by 56% to 86,036 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Binkowski Brent was granted 15,000 shares, increasing direct ownership by 90% to 31,600 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- SECCVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
- PRCVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual MeetingMINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting. THT, the annual conference organized by the Cardiovascular Research Foundation® (CRF®), will be held March 2-4, 2026, in Boston, Massachusetts. The presentations include late-breaking clinical data, oral sessions and posters highlighting real-world outcomes, cardiac energetics, h
- INSIDERDirector Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERDirector Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- SECSEC Form S-8 filed by CVRx Inc.S-8 - CVRx, Inc. (0001235912) (Filer)
- SECSEC Form 10-K filed by CVRx Inc.10-K - CVRx, Inc. (0001235912) (Filer)
- SECCVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
- PRCVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsMINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarterTotal revenue for 2025 was $56.7 million, an increase of 10% over the prior yearActive implanting centers
- PRCVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone
- PRCVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded PopulationMINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced initiation of the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS Category B IDE coverage and designed to evaluate the impact of Barostim™ in a significantly expanded heart failure population. Barostim™ is an implantable device that delivers electrical signals to baroreceptors located on the carotid artery, increasing baroreflex signaling, rebalancing the autonomic nervous system, and improving heart failure symptoms.
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CVRx Inc.SCHEDULE 13G/A - CVRx, Inc. (0001235912) (Subject)
- SECCVRx Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
CVRX FAQ
6 questionsWhere does CVRX stock trade?
CVRx Inc. (CVRX) is listed on NASDAQ.What sector and industry is CVRX in?
CVRx Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did CVRx Inc. go public?
CVRx Inc. (CVRX) completed its IPO in 2021.What are analysts saying about CVRX?
CVRx Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Underweight with a $700.00 price target on 2025-05-09. Recent price targets range from $700.00 to $2300.00.What companies are similar to CVRX?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare CVRX side-by-side with any of them on Quantisnow.How can I track CVRX on Quantisnow?
Quantisnow aggregates CVRx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CVRX to receive live email and push alerts on every new disclosure.